Loading page…
Kaken Pharmaceutical Co Ltd 2014 Annual Report with Sustainability Disclosures
Company: Kaken Pharmaceutical Co Ltd
Sector: Manufacturing
Country: Japan
Year: 2014
Type: Annual Report with Sustainability Disclosures
Pages: 50
The report highlights Japan's 2014 approval of Kaken-developed efinaconazole as the country's first topical onychomycosis medication. Consolidated net sales were ¥88,946 million for the year. The Shizuoka Factory reported 5,625 tons of waste, all used for composting, and the report also describes company-wide environmental initiatives.
No ESG data is available for this report.